Founded in 2019, Gannex, a wholly-owned company of Ascletis Pharma Inc. (1672.HK), is dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets — FASN, THR-β and FXR — and three combination therapies.
For more information, please view: 
Gannex Corporate Presentation.pdf
Email：
pr@gannexpharma.com
ir@gannexpharma.com
hr@gannexpharma.com
All contents © Copyright Gannex Pharma Co., Ltd.All Rights Reserved
This site is published by Gannex Pharma Co., Ltd.
which is solely responsible for all site content.
